← TREACE MEDICAL CONCEPTS, INC.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Net loss | ($4.3m) | ($3.7m) | ($20.6m) | ($42.8m) | ($49.5m) | ($55.7m) | ($59.0m) | — | |
| Depreciation and amortization expense | $793k | $1.2m | $685k | $2.1m | $5.4m | $8.4m | $10.6m | $8.4m | |
| Amortization of debt issuance costs | $147k | $220k | $176k | $244k | $297k | $298k | $292k | — | |
| Amortization (accretion) of premium (discount) on marketable securities, net | — | $0 | $0 | ($126k) | ($1.4m) | ($1.1m) | ($123k) | — | |
| Share-based compensation expense | $815k | $919k | $3.4m | $8.1m | $17.4m | $30.6m | $33.8m | $30.1m | |
| Loss on impairment of long-lived assets | — | $0 | $0 | $346k | $0 | $0 | — | — | |
| Accounts receivable | ($6.0m) | ($4.3m) | ($4.2m) | ($11.0m) | ($9.3m) | ($5.7m) | ($2.1m) | $1.1m | |
| Inventory | ($2.8m) | ($3.4m) | ($3.1m) | ($8.8m) | ($9.8m) | ($10.0m) | $3.2m | $2.9m | |
| Accounts payable | ($236k) | $1.3m | $1.8m | $4.6m | $3.2m | ($1.3m) | ($3.8m) | ($3.9m) | |
| Accrued liabilities | $3.9m | $1.1m | $6.6m | $7.1m | $7.5m | ($7.9m) | ($2.4m) | $2.5m | |
| Conversion of convertible preferred stock and accrued dividends on convertible preferred stock into common stock | — | $0 | $7.9m | $0 | $0 | — | — | — | |
| Prepaid expenses and other assets | ($94k) | ($103k) | ($2.4m) | ($668k) | ($1.2m) | $2.2m | $166k | — | |
| Other liabilities | — | — | $0 | $3.1m | ($119k) | — | — | — | |
| Net cash provided by (used in) operating activities | ($7.7m) |
($4.5m)
+41.43%
|
($17.2m)
-282.58%
|
($30.6m)
-78.26%
|
($34.6m)
-12.81%
|
($37.2m)
-7.50%
|
($16.0m)
+57.03%
|
($14.6m)
+8.73%
|
|
| Purchases of property and equipment | ($1.2m) | ($1.1m) | ($2.7m) | ($14.8m) | ($11.5m) | ($11.6m) | ($13.5m) | ($10.5m) | |
| Purchases of available-for-sale marketable securities | — | $0 | $0 | ($63.4m) | ($169.9m) | ($71.6m) | ($40.6m) | — | |
| Sales and maturities of available-for-sale marketable securities | — | $0 | $0 | $1.7m | $120.0m | $118.5m | $67.3m | — | |
| Unrealized (gains) losses, net on marketable securities | — | $0 | $0 | $27k | ($190k) | $66k | $25k | — | |
| Net cash provided by (used in) investing activities | ($1.2m) | ($1.1m) | ($2.7m) | ($76.5m) | ($81.3m) | $35.4m | $13.3m | $17.7m | |
| Debt extinguishment loss | — | $639k | $0 | $4.5m | $0 | $0 | $2.7m | — | |
| Proceeds from interest bearing term debt | — | — | $0 | $49.7m | $0 | $0 | $59.3m | — | |
| Proceeds from interest bearing revolving debt | — | $0 | $0 | $3.9m | $0 | $0 | — | — | |
| Debt issuance costs | ($329k) | ($179k) | $0 | ($989k) | $0 | $0 | ($1.2m) | — | |
| Payments on interest bearing term and revolving debt | — | — | — | — | $0 | $0 | ($56.3m) | — | |
| Payments on interest bearing debt | — | ($20.0m) | $0 | ($33.9m) | $0 | $0 | — | — | |
| Proceeds from issuance of common stock from public offering, net of issuance costs and underwriting discount of $7.5 million | — | $0 | $107.6m | $0 | $107.5m | $0 | $0 | $0 | |
| Issuance of common stock upon exercise of warrants | — | $0 | $1k | $0 | $0 | — | — | $0 | |
| Net cash provided by (used in) financing activities | $19.7m |
$11.5m
-41.72%
|
$107.7m
+835.86%
|
$20.8m
-80.67%
|
$109.4m
+425.73%
|
$160k
-99.85%
|
$2.1m
+1198.12%
|
$1.5m
-28.74%
|
|
| Net increase (decrease) in cash and cash equivalents | $10.9m | $5.9m | $87.8m | ($86.4m) | ($6.5m) | ($1.6m) | ($642k) | — | |
| Cash and cash equivalents at beginning of period | $1.3m | $12.1m | $18.1m | $19.5m | $13.0m | $11.3m | $10.7m | — | |
| Additional Supplementary Disclosures | |||||||||
| Additional Supplementary Disclosures | |||||||||
| Provision for allowance for credit losses | — | — | — | $411k | $434k | $2.9m | $834k | — | |
| Non-cash lease expense | — | $0 | $0 | $2.5m | $2.5m | $2.3m | $2.2m | — | |
| Gain on fair value adjustment to derivative liability | — | $0 | ($72k) | ($173k) | $0 | $0 | — | — | |
| Other, net | — | $0 | $0 | $25k | $40k | $97k | $35k | — | |
| Other non-current assets | — | $0 | $0 | ($146k) | $0 | ($330k) | ($503k) | — | |
| Operating lease liabilities | — | $0 | $0 | $3.1m | ($119k) | ($2.5m) | ($3.2m) | — | |
| Acquisition, net of cash acquired | — | — | $0 | $0 | ($20.0m) | $0 | $0 | — | |
| Proceeds from insurance premium financing | — | — | — | — | $0 | $0 | $1.6m | — | |
| Payments on insurance premium financing | — | — | — | — | $0 | $0 | ($916k) | — | |
| Payments on PPP Loan | — | $0 | ($1.8m) | $0 | $0 | — | — | — | |
| Proceeds from exercise of employee stock options | $68k | $364k | $1.8m | $2.2m | $1.9m | $428k | $546k | — | |
| Taxes from withheld shares | — | — | $0 | $0 | ($13k) | ($268k) | ($902k) | — | |
| Cash paid for interest | $739k | $1.1m | $3.9m | $4.4m | $5.2m | $5.0m | $5.0m | — | |
| Operating lease right-of-use assets obtained in exchange for new lease liabilities | — | $0 | $0 | $15.3m | $0 | $0 | — | — | |
| Operating lease right-of-use asset and lease liability adjustment due to lease incentive | — | $0 | $0 | $3.6m | ($22k) | $8k | $0 | — | |
| Noncash portion of internally developed software | — | — | $0 | $0 | ($11k) | $0 | $0 | — | |
| Unsettled matured marketable security and receivable from broker | — | — | $0 | $0 | $3.0m | $0 | $0 | — | |
| Legal cost financing | — | — | — | — | $0 | $0 | $1.1m | — |